CERAMED is pioneering personalized medicine through innovative prognostic solutions that go beyond traditional diagnostics. In partnership with leading French and German medical institutions (AP-HP, UK Erlangen, FU Berlin), we're developing tests that predict treatment response in major depressive disorder management and its potential aggravations.

​

Our technology combines the best of biology and technology: patented biomarkers with advanced algorithms to provide practitioners with actionable insights within 72 hours from a simple blood test. This approach enables early intervention and treatment optimization to prevent clinical deterioration, particularly for patients at risk of treatment resistance or severe cognitive decline. After successfully demonstrating our proof of concept efficacy in predicting severe COVID-19 inflammation (CeraCOV®), we are now deploying our technology in neuro-inflammation care.

​

Our new solutions, CeraDOSE® and CeraBRAIN®, will help clinicians optimize care and identify early risks of unfavorable evolution through standardized blood analysis. Qualified as Deeptech by Bpifrance in 2023, CERAMED is leading a European scientific effort across 7 major clinical centers to publish the first neuropsychiatric results by 2026. Our tests will be widely available from early 2028 through partnerships with medical laboratory networks.